CN101680002A - 一组重组腺相关病毒载体及其构建方法与应用 - Google Patents
一组重组腺相关病毒载体及其构建方法与应用 Download PDFInfo
- Publication number
- CN101680002A CN101680002A CN200880012949A CN200880012949A CN101680002A CN 101680002 A CN101680002 A CN 101680002A CN 200880012949 A CN200880012949 A CN 200880012949A CN 200880012949 A CN200880012949 A CN 200880012949A CN 101680002 A CN101680002 A CN 101680002A
- Authority
- CN
- China
- Prior art keywords
- raav
- gene
- antigen
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013603 viral vector Substances 0.000 title claims abstract description 159
- 238000000034 method Methods 0.000 title claims abstract description 149
- 238000010276 construction Methods 0.000 title claims abstract description 9
- 230000008569 process Effects 0.000 title abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 309
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 305
- 210000004027 cell Anatomy 0.000 claims abstract description 218
- 108091007433 antigens Proteins 0.000 claims abstract description 214
- 238000011282 treatment Methods 0.000 claims abstract description 149
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 144
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims abstract description 106
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims abstract description 103
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims abstract description 67
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 53
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 52
- 201000011510 cancer Diseases 0.000 claims abstract description 50
- 101710192602 Latent membrane protein 1 Proteins 0.000 claims abstract description 41
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 37
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims abstract description 31
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 29
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims abstract description 25
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims abstract description 25
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims abstract description 25
- 201000007270 liver cancer Diseases 0.000 claims abstract description 21
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 21
- 210000004072 lung Anatomy 0.000 claims abstract description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 16
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims abstract description 14
- 210000004907 gland Anatomy 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims abstract description 8
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 4
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 4
- 201000005202 lung cancer Diseases 0.000 claims abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 4
- 102100038358 Prostate-specific antigen Human genes 0.000 claims abstract 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 299
- 239000013612 plasmid Substances 0.000 claims description 224
- 239000000427 antigen Substances 0.000 claims description 158
- 102000036639 antigens Human genes 0.000 claims description 158
- 208000015181 infectious disease Diseases 0.000 claims description 131
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 88
- 230000002147 killing effect Effects 0.000 claims description 86
- 102000007469 Actins Human genes 0.000 claims description 57
- 108010085238 Actins Proteins 0.000 claims description 57
- 208000029742 colonic neoplasm Diseases 0.000 claims description 34
- 230000003612 virological effect Effects 0.000 claims description 22
- 108010066302 Keratin-19 Proteins 0.000 claims description 17
- 206010017758 gastric cancer Diseases 0.000 claims description 15
- 201000011549 stomach cancer Diseases 0.000 claims description 15
- 208000019065 cervical carcinoma Diseases 0.000 claims description 13
- 238000001890 transfection Methods 0.000 claims description 7
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 210000005075 mammary gland Anatomy 0.000 claims description 4
- 230000002269 spontaneous effect Effects 0.000 claims description 4
- 230000000527 lymphocytic effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 102000004641 Fetal Proteins Human genes 0.000 claims description 2
- 108010003471 Fetal Proteins Proteins 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 108010042653 IgA receptor Proteins 0.000 claims description 2
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 230000009876 antimalignant effect Effects 0.000 claims 2
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 99
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 abstract description 74
- 102100039648 Lactadherin Human genes 0.000 abstract description 70
- 238000002474 experimental method Methods 0.000 abstract description 36
- 230000012010 growth Effects 0.000 abstract description 27
- 230000003211 malignant effect Effects 0.000 abstract description 25
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 19
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 19
- 201000010881 cervical cancer Diseases 0.000 abstract description 19
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 3
- 239000012636 effector Substances 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 abstract 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 abstract 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 abstract 1
- 101710123134 Ice-binding protein Proteins 0.000 abstract 1
- 101710082837 Ice-structuring protein Proteins 0.000 abstract 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 abstract 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 abstract 1
- 201000010989 colorectal carcinoma Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
- 210000000605 viral structure Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 description 178
- 238000006243 chemical reaction Methods 0.000 description 177
- 239000012634 fragment Substances 0.000 description 143
- 238000012360 testing method Methods 0.000 description 134
- 241000700605 Viruses Species 0.000 description 129
- 108020004414 DNA Proteins 0.000 description 105
- 238000001514 detection method Methods 0.000 description 105
- 108091008146 restriction endonucleases Proteins 0.000 description 98
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 95
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 85
- 230000029087 digestion Effects 0.000 description 82
- 101710183399 Keratin, type I cytoskeletal 19 Proteins 0.000 description 73
- 230000014509 gene expression Effects 0.000 description 70
- 210000002966 serum Anatomy 0.000 description 70
- 238000012408 PCR amplification Methods 0.000 description 69
- 230000008859 change Effects 0.000 description 66
- 238000000246 agarose gel electrophoresis Methods 0.000 description 49
- 239000002773 nucleotide Substances 0.000 description 49
- 125000003729 nucleotide group Chemical group 0.000 description 49
- 239000007853 buffer solution Substances 0.000 description 48
- 239000003643 water by type Substances 0.000 description 48
- 230000000694 effects Effects 0.000 description 47
- 239000000523 sample Substances 0.000 description 40
- 210000001519 tissue Anatomy 0.000 description 40
- 230000001394 metastastic effect Effects 0.000 description 39
- 206010061289 metastatic neoplasm Diseases 0.000 description 39
- 230000003902 lesion Effects 0.000 description 38
- 230000000118 anti-neoplastic effect Effects 0.000 description 37
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 description 35
- 210000001616 monocyte Anatomy 0.000 description 35
- 239000000047 product Substances 0.000 description 35
- 230000004087 circulation Effects 0.000 description 33
- 238000002360 preparation method Methods 0.000 description 33
- 238000000746 purification Methods 0.000 description 33
- 102100035793 CD83 antigen Human genes 0.000 description 32
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 32
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 32
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 32
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 32
- 238000003306 harvesting Methods 0.000 description 32
- 238000009396 hybridization Methods 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 31
- 239000000969 carrier Substances 0.000 description 29
- 210000004698 lymphocyte Anatomy 0.000 description 28
- 230000034994 death Effects 0.000 description 27
- 230000003321 amplification Effects 0.000 description 26
- 238000005516 engineering process Methods 0.000 description 26
- 238000003199 nucleic acid amplification method Methods 0.000 description 26
- 210000002845 virion Anatomy 0.000 description 26
- 102100031780 Endonuclease Human genes 0.000 description 24
- 108010042407 Endonucleases Proteins 0.000 description 24
- 102000003960 Ligases Human genes 0.000 description 24
- 108090000364 Ligases Proteins 0.000 description 24
- 239000000463 material Substances 0.000 description 24
- 108020004999 messenger RNA Proteins 0.000 description 24
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 22
- 238000011084 recovery Methods 0.000 description 20
- 238000001415 gene therapy Methods 0.000 description 19
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 18
- 238000003780 insertion Methods 0.000 description 18
- 230000037431 insertion Effects 0.000 description 18
- 239000007850 fluorescent dye Substances 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 206010067484 Adverse reaction Diseases 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 108700019961 Neoplasm Genes Proteins 0.000 description 16
- 102000048850 Neoplasm Genes Human genes 0.000 description 16
- 239000004677 Nylon Substances 0.000 description 16
- 230000006838 adverse reaction Effects 0.000 description 16
- 244000309466 calf Species 0.000 description 16
- 229910002092 carbon dioxide Inorganic materials 0.000 description 16
- 239000001569 carbon dioxide Substances 0.000 description 16
- 238000001476 gene delivery Methods 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 238000002372 labelling Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 229920001778 nylon Polymers 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 15
- 230000001665 lethal effect Effects 0.000 description 15
- 238000011895 specific detection Methods 0.000 description 15
- 108091006146 Channels Proteins 0.000 description 13
- 230000005867 T cell response Effects 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 229930193140 Neomycin Natural products 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000013599 cloning vector Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 229960004927 neomycin Drugs 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 241000341655 Human papillomavirus type 16 Species 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 238000005034 decoration Methods 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000001215 fluorescent labelling Methods 0.000 description 9
- 238000013467 fragmentation Methods 0.000 description 9
- 238000006062 fragmentation reaction Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 230000004544 DNA amplification Effects 0.000 description 8
- 239000003298 DNA probe Substances 0.000 description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 8
- 206010019663 Hepatic failure Diseases 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 108010063738 Interleukins Proteins 0.000 description 8
- 102000015696 Interleukins Human genes 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000036528 appetite Effects 0.000 description 8
- 235000019789 appetite Nutrition 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 201000006370 kidney failure Diseases 0.000 description 8
- 208000007903 liver failure Diseases 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000007447 staining method Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000008676 import Effects 0.000 description 7
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 5
- 108020003215 DNA Probes Proteins 0.000 description 4
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 description 2
- 101100001670 Emericella variicolor andE gene Proteins 0.000 description 2
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 241001286657 Psavirus Species 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101150045267 CEA gene Proteins 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101150055123 afp gene Proteins 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 101150034144 ci gene Proteins 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003360 nephrocyte Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464481—Alpha-feto protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464495—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/52—Intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一组重组腺相关病毒载体(rAAV)及其构建方法与其应用。该rAAV是将腺相关病毒载体中的腺相关病毒结构基因替换为肿瘤抗原基因PSA、PSMA、CEA、CK19、Her－2/neu、LMP－1、BA46或AFP或其突变型基因得到。本发明的rAAV可将其携带的野生型或突变型的前列腺特异性抗原基因输送入单核细胞－巨噬细胞－树突状细胞系中，被用于刺激免疫系统的效应细胞。实验证明，被本发明的rAAV感染的DC所诱导的CTL在患者体内可有效地抑制恶性肿瘤细胞的生长或者杀灭肿瘤细胞。本发明的重组腺相关病毒载体或其相关产品可被用于制备治疗前列腺癌、上皮细胞恶性肿瘤、乳腺癌、结肠癌、胃癌、肺腺癌、肺癌、卵巢癌、鼻咽癌、宫颈癌、肺鳞癌、肝癌等的药物。
Description
PCT国内申请，说明书已公开。
Claims (1)
- PCT国内申请，权利要求书已公开。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008800129496A CN101680002B (zh) | 2007-04-23 | 2008-04-23 | 一组重组腺相关病毒载体及其构建方法与应用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710097935.6 | 2007-04-23 | ||
| CN200710097935 | 2007-04-23 | ||
| CN2008800129496A CN101680002B (zh) | 2007-04-23 | 2008-04-23 | 一组重组腺相关病毒载体及其构建方法与应用 |
| PCT/CN2008/000835 WO2008128440A1 (fr) | 2007-04-23 | 2008-04-23 | Série de vecteurs recombinés dérivés du virus adéno-associé (raav), leurs procédés de construction et leurs utilisations |
Related Child Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101256030A Division CN102277384B (zh) | 2007-04-23 | 2008-04-23 | 一种psa重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256327A Division CN102268454B (zh) | 2007-04-23 | 2008-04-23 | 一种psma重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256609A Division CN102268456B (zh) | 2007-04-23 | 2008-04-23 | 一种Her-2/neu重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256971A Division CN102268458B (zh) | 2007-04-23 | 2008-04-23 | 一种ba46重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256651A Division CN102268453B (zh) | 2007-04-23 | 2008-04-23 | 一种lmp-1重组腺相关病毒载体及其构建方法与应用 |
| CN201110125683XA Division CN102268457B (zh) | 2007-04-23 | 2008-04-23 | 一种afp重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256435A Division CN102268455B (zh) | 2007-04-23 | 2008-04-23 | 一种cea重组腺相关病毒载体及其构建方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101680002A true CN101680002A (zh) | 2010-03-24 |
| CN101680002B CN101680002B (zh) | 2011-11-23 |
Family
ID=39875079
Family Applications (16)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800129496A Active CN101680002B (zh) | 2007-04-23 | 2008-04-23 | 一组重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256435A Active CN102268455B (zh) | 2007-04-23 | 2008-04-23 | 一种cea重组腺相关病毒载体及其构建方法与应用 |
| CN201110125683XA Active CN102268457B (zh) | 2007-04-23 | 2008-04-23 | 一种afp重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932246A Withdrawn CN101307330A (zh) | 2007-04-23 | 2008-04-23 | 一种ba46重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932212A Withdrawn CN101307327A (zh) | 2007-04-23 | 2008-04-23 | 一种cea重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256609A Active CN102268456B (zh) | 2007-04-23 | 2008-04-23 | 一种Her-2/neu重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256971A Active CN102268458B (zh) | 2007-04-23 | 2008-04-23 | 一种ba46重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256030A Active CN102277384B (zh) | 2007-04-23 | 2008-04-23 | 一种psa重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256327A Active CN102268454B (zh) | 2007-04-23 | 2008-04-23 | 一种psma重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932265A Withdrawn CN101255442A (zh) | 2007-04-23 | 2008-04-23 | 一种lmp-1重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932250A Withdrawn CN101255441A (zh) | 2007-04-23 | 2008-04-23 | 一种afp重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932231A Withdrawn CN101307329A (zh) | 2007-04-23 | 2008-04-23 | 一种Her-2/neu重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932227A Withdrawn CN101307328A (zh) | 2007-04-23 | 2008-04-23 | 一种ck19重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256651A Active CN102268453B (zh) | 2007-04-23 | 2008-04-23 | 一种lmp-1重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932208A Withdrawn CN101307326A (zh) | 2007-04-23 | 2008-04-23 | 一种psa重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932195A Withdrawn CN101307325A (zh) | 2007-04-23 | 2008-04-23 | 一种psma重组腺相关病毒载体及其构建方法与应用 |
Family Applications After (15)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101256435A Active CN102268455B (zh) | 2007-04-23 | 2008-04-23 | 一种cea重组腺相关病毒载体及其构建方法与应用 |
| CN201110125683XA Active CN102268457B (zh) | 2007-04-23 | 2008-04-23 | 一种afp重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932246A Withdrawn CN101307330A (zh) | 2007-04-23 | 2008-04-23 | 一种ba46重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932212A Withdrawn CN101307327A (zh) | 2007-04-23 | 2008-04-23 | 一种cea重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256609A Active CN102268456B (zh) | 2007-04-23 | 2008-04-23 | 一种Her-2/neu重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256971A Active CN102268458B (zh) | 2007-04-23 | 2008-04-23 | 一种ba46重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256030A Active CN102277384B (zh) | 2007-04-23 | 2008-04-23 | 一种psa重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256327A Active CN102268454B (zh) | 2007-04-23 | 2008-04-23 | 一种psma重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932265A Withdrawn CN101255442A (zh) | 2007-04-23 | 2008-04-23 | 一种lmp-1重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932250A Withdrawn CN101255441A (zh) | 2007-04-23 | 2008-04-23 | 一种afp重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932231A Withdrawn CN101307329A (zh) | 2007-04-23 | 2008-04-23 | 一种Her-2/neu重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932227A Withdrawn CN101307328A (zh) | 2007-04-23 | 2008-04-23 | 一种ck19重组腺相关病毒载体及其构建方法与应用 |
| CN2011101256651A Active CN102268453B (zh) | 2007-04-23 | 2008-04-23 | 一种lmp-1重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932208A Withdrawn CN101307326A (zh) | 2007-04-23 | 2008-04-23 | 一种psa重组腺相关病毒载体及其构建方法与应用 |
| CNA2008100932195A Withdrawn CN101307325A (zh) | 2007-04-23 | 2008-04-23 | 一种psma重组腺相关病毒载体及其构建方法与应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (16) | CN101680002B (zh) |
| WO (1) | WO2008128440A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11761020B2 (en) | 2020-10-15 | 2023-09-19 | Aavocyte, Inc. | Recombinant adeno-associated virus vectors with CD14 promoter and use thereof |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101775375B (zh) * | 2009-07-31 | 2013-04-10 | 华中科技大学同济医学院附属同济医院 | 制备含eb病毒潜伏膜蛋白1,2基因的重组腺相关病毒及其应用 |
| CN101638655B (zh) * | 2009-09-03 | 2011-05-04 | 杭州安倍生物科技有限公司 | 癌胚抗原阳性细胞靶向性基因表达元件cpe及其应用 |
| CN105316361B (zh) * | 2014-08-01 | 2017-11-28 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型突变型E7m58抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105177047B (zh) * | 2014-08-12 | 2018-02-02 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105177048B (zh) * | 2014-08-12 | 2018-02-02 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105018525B (zh) * | 2014-08-12 | 2017-06-13 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型突变型E7m91抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN104830800A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于psma抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| CN104830780A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于ba46抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| CN104830782A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于ck19抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| CN105969804B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带scc抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105985984B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 携带pap抗原基因的重组腺相关病毒载体及构建方法与应用 |
| CN105087649B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 携带muc-1抗原基因的重组腺相关病毒载体及构建方法与应用 |
| CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
| CN106591370A (zh) * | 2015-10-19 | 2017-04-26 | 南京华贞生物医药科技有限公司 | 一种治疗自身免疫性相关疾病以及糖尿病的病毒载体及其构建方法和应用 |
| CN106119231A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种肿瘤抗原psa的ctl识别表位肽及其应用 |
| CN106282234B (zh) * | 2016-08-05 | 2020-11-13 | 深圳前海美康医疗生物技术有限公司 | 携带人c基因型乙型肝炎病毒的表面抗原s基因的重组腺相关病毒载体及其构建方法与应用 |
| CN108546715A (zh) * | 2018-01-19 | 2018-09-18 | 广东拓谱康生物科技有限公司 | 一种lmp-2重组腺相关病毒载体及其构建方法与应用 |
| CN108841867A (zh) * | 2018-06-11 | 2018-11-20 | 北京安斯晨睿生物科技有限公司 | 携带 scc/bst2 突变抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN108642085A (zh) * | 2018-06-11 | 2018-10-12 | 北京安斯晨睿生物科技有限公司 | 携带bcma突变抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN108753825A (zh) * | 2018-06-11 | 2018-11-06 | 北京安斯晨睿生物科技有限公司 | 携带her2/erbb突变抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN108893490A (zh) * | 2018-07-25 | 2018-11-27 | 北京安斯晨睿生物科技有限公司 | 携带ceacam8突变抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN109234314B (zh) * | 2018-10-16 | 2022-06-07 | 汉恒生物科技（上海）有限公司 | 用于敲除cxcl12基因的腺相关病毒重组载体及其构建方法和用途 |
| CN110885855A (zh) * | 2018-11-02 | 2020-03-17 | 深圳益世康宁生物科技有限公司 | 一种携带精子蛋白17抗原基因的重组腺相关病毒载体及其应用价值 |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| JP7315965B2 (ja) * | 2018-11-09 | 2023-07-27 | 積水メディカル株式会社 | ウィルス性肝癌の検出方法 |
| CN111647606B (zh) * | 2020-08-06 | 2020-11-27 | 北京翊博普惠生物科技发展有限公司 | 靶向afp全抗原的dc细胞、ctl细胞及其制备方法和应用 |
| CN116355058A (zh) * | 2020-11-12 | 2023-06-30 | 天津大学 | Eb病毒抗原表位及其应用 |
| CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US6652850B1 (en) * | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| CN100402655C (zh) * | 2005-03-17 | 2008-07-16 | 中山大学中山医学院科技开发中心 | 人神经营养素-3受体基因重组腺病毒构建方法 |
-
2008
- 2008-04-23 CN CN2008800129496A patent/CN101680002B/zh active Active
- 2008-04-23 CN CN2011101256435A patent/CN102268455B/zh active Active
- 2008-04-23 CN CN201110125683XA patent/CN102268457B/zh active Active
- 2008-04-23 CN CNA2008100932246A patent/CN101307330A/zh not_active Withdrawn
- 2008-04-23 CN CNA2008100932212A patent/CN101307327A/zh not_active Withdrawn
- 2008-04-23 CN CN2011101256609A patent/CN102268456B/zh active Active
- 2008-04-23 WO PCT/CN2008/000835 patent/WO2008128440A1/zh active Application Filing
- 2008-04-23 CN CN2011101256971A patent/CN102268458B/zh active Active
- 2008-04-23 CN CN2011101256030A patent/CN102277384B/zh active Active
- 2008-04-23 CN CN2011101256327A patent/CN102268454B/zh active Active
- 2008-04-23 CN CNA2008100932265A patent/CN101255442A/zh not_active Withdrawn
- 2008-04-23 CN CNA2008100932250A patent/CN101255441A/zh not_active Withdrawn
- 2008-04-23 CN CNA2008100932231A patent/CN101307329A/zh not_active Withdrawn
- 2008-04-23 CN CNA2008100932227A patent/CN101307328A/zh not_active Withdrawn
- 2008-04-23 CN CN2011101256651A patent/CN102268453B/zh active Active
- 2008-04-23 CN CNA2008100932208A patent/CN101307326A/zh not_active Withdrawn
- 2008-04-23 CN CNA2008100932195A patent/CN101307325A/zh not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11761020B2 (en) | 2020-10-15 | 2023-09-19 | Aavocyte, Inc. | Recombinant adeno-associated virus vectors with CD14 promoter and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102268456A (zh) | 2011-12-07 |
| WO2008128440A1 (fr) | 2008-10-30 |
| CN102268453A (zh) | 2011-12-07 |
| CN102268457B (zh) | 2013-06-26 |
| CN102268458B (zh) | 2013-04-03 |
| CN101307330A (zh) | 2008-11-19 |
| CN101680002B (zh) | 2011-11-23 |
| CN101255442A (zh) | 2008-09-03 |
| CN101307327A (zh) | 2008-11-19 |
| CN102268455A (zh) | 2011-12-07 |
| CN102277384A (zh) | 2011-12-14 |
| CN102268453B (zh) | 2013-04-03 |
| CN102277384B (zh) | 2013-06-26 |
| CN101255441A (zh) | 2008-09-03 |
| CN102268458A (zh) | 2011-12-07 |
| CN102268457A (zh) | 2011-12-07 |
| CN102268454B (zh) | 2013-07-24 |
| CN101307325A (zh) | 2008-11-19 |
| CN101307329A (zh) | 2008-11-19 |
| CN102268455B (zh) | 2013-09-18 |
| CN102268454A (zh) | 2011-12-07 |
| CN101307326A (zh) | 2008-11-19 |
| CN101307328A (zh) | 2008-11-19 |
| CN102268456B (zh) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101680002B (zh) | 一组重组腺相关病毒载体及其构建方法与应用 | |
| CN105985984B (zh) | 携带pap抗原基因的重组腺相关病毒载体及构建方法与应用 | |
| CN105087648B (zh) | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 | |
| CN105087647B (zh) | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| WO2016015684A1 (zh) | 携带人乳头瘤病毒16型突变型e7抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN105018525B (zh) | 携带人乳头瘤病毒16型突变型E7m91抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN105177048B (zh) | 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN105087649B (zh) | 携带muc-1抗原基因的重组腺相关病毒载体及构建方法与应用 | |
| CN105969804B (zh) | 一种携带scc抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN108546715A (zh) | 一种lmp-2重组腺相关病毒载体及其构建方法与应用 | |
| CN105177047B (zh) | 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN105316361B (zh) | 携带人乳头瘤病毒16型突变型E7m58抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN110684800B (zh) | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 | |
| CN111088286B (zh) | 一种重组腺相关病毒载体的构建和制备及其应用价值 | |
| CN110885855A (zh) | 一种携带精子蛋白17抗原基因的重组腺相关病毒载体及其应用价值 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HEALTH POWER BIOMED (TIAN JIN) INC. Free format text: FORMER OWNER: LIU YONG Effective date: 20100914 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510663 SUITE 203, NO.7, YUNGUI STREET, YUNJING ROAD, GUANGZHOU CITY, GUANGDONG PROVINCE, CHINA TO: 300457 S1306, 13/F, LAB BUILDING, TIANJIN INTERNATIONAL JOINT RESEARCH INSTITUTE OF BIOMEDICINE, NO.220, DONGTING ROAD, TIANJIN DEVELOPMENT AREA, TIANJIN CITY |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100914 Address after: Thirteen Tianjin building, 300457 / F, experimental building, Tianjin international biological medicine Joint Research Institute, 220 Dongting Road, Tianjin Development Zone, S1306 Applicant after: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. Address before: Cloud View Road Yungui street in Guangzhou City, Guangdong province 510663 Chinese No. 7 Room 203 Applicant before: Liu Yong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN IMMUCLIN BIOMED, INC. Free format text: FORMER OWNER: HEALTH POWER BIOMED (TIANJIN) INC. Effective date: 20121121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300457 HANGU, TIANJIN TO: 518057 SHENZHEN, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121121 Address after: 518057 Guangdong Province, Shenzhen high tech Zone of Nanshan District City, North Beihuan Road Song Ping Road No. 1 building fifteen South Liteon room 1503 Patentee after: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. Address before: Thirteen Tianjin building, 300457 / F, experimental building, Tianjin international biological medicine Joint Research Institute, 220 Dongting Road, Tianjin Development Zone, S1306 Patentee before: Health-Power Biological Medical Technology (Tianjin) Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190918 Address after: 518000 Tongfang Information Port A Block 701, No. 11 Longshan Road, Songpingshan Community, Xili Street, Nanshan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Yishi Kangning Biomedical Development Co., Ltd. Address before: 518057 Guangdong Province, Shenzhen high tech Zone of Nanshan District City, North Beihuan Road Song Ping Road No. 1 building fifteen South Liteon room 1503 Patentee before: Shenzhen Yishi Kangning Biotechnology Co., Ltd. |